UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
 
SCHEDULE 13G
 
Under the Securities Exchange Act of 1934
(Amendment No.  )*
 
 
EyeGate Pharmaceuticals, Inc.
(Name of Issuer)
 
 
 
Common Stock, $0.01 par value per share
(Title of Class of Securities)
 
 
 
30233M503
(CUSIP Number)
 
 
N/A
(Date of Event Which Requires Filing of this Statement)
 
 
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
[X] Rule 13d-1(b)
 
[_] Rule 13d-1(c)
 
[_] Rule 13d-1(d)
 
__________
* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 
   CUSIP No. 30233M503
 
 
 
1.
NAME OF REPORTING PERSONS
 
 
 
 
 
Armistice Capital, LLC
 
 
 
 
2.
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
 
 
(a)  [_]
 
 
(b)  [_]
3.
SEC USE ONLY
 
 
 
 
 
 
 
4.
CITIZENSHIP OR PLACE OF ORGANIZATION
 
 
 
 
 
Delaware
 
 
 
 
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
 
 
 
5.
SOLE VOTING POWER
 
 
 
 
 
0
 
 
 
 
6.
SHARED VOTING POWER
 
 
 
 
 

2,916,101
 
 
 
 
7.
SOLE DISPOSITIVE POWER
 
 
 
 
 
0
 
 
 
 
8.
SHARED DISPOSITIVE POWER
 
 
 
 
 

2,916,101
 
 
 
 
9.
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 
 
 
 

2,916,101
 
 
 
 
10.
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
 
 
 
[_]
 
 
 
11.
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
 
 
 
 
 
19.8%
 
 
 
 
12.
TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
 
 
 
 
 
IA, OO
 
 
  
 
CUSIP No. 30233M503
 
 
 
1.
NAME OF REPORTING PERSONS
 
 
 
 
 
Steven Boyd
 
 
 
 
2.
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
 
 
(a)  [_]
 
 
(b)  [_]
 
 
 
3.
SEC USE ONLY
 
 
 
 
 
 
 
4.
CITIZENSHIP OR PLACE OF ORGANIZATION
 
 
 
 
 
United States of America
 
 
 
 
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
 
 
 
5.
SOLE VOTING POWER
 
 
 
 
 
0
 
 
 
 
6.
SHARED VOTING POWER
 
 
 
 
 
2,916,101
 
 
 
 
7.
SOLE DISPOSITIVE POWER
 
 
 
 
 
0
 
 
 
 
8.
SHARED DISPOSITIVE POWER
 
 
 
 
 
2,916,101
 
 
 
 
9.
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 
 
 
 
2,916,101
 
 
 
 
10.
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
 
 
 
[_]
 
 
 
11.
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
 
 
 
 
 
19.8%
 
 
 
 
12.
TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
 
 
 
 
 
IN, HC
 
 


Item 1.
(a).
Name of Issuer:
 
 
 
 
EyeGate Pharmaceuticals, Inc. (the “Issuer”)
 
 
 
 
 
 
(b).
Address of Issuer's Principal Executive Offices:
 
 
 
 
 
 
 
271 Waverley Oaks Road
Suite 108
Waltham, MA 02452
 
 
 
 
 
 
 
 
 
Item 2.
(a).
Name of Person Filing:
 
 
 
 
 
 
 
Armistice Capital, LLC
Steven Boyd
 
Collectively, the “Reporting Persons”
 
 
 
 
 
 
(b).
Address of Principal Business Office, or if None, Residence:
 
 
 
 
 
 
 
Armistice Capital, LLC
510 Madison Avenue, 7th Floor
New York, New York 10022
United States of America
 
Steven Boyd
c/o Armistice Capital, LLC
510 Madison Avenue, 7th Floor
New York, New York 10022
United States of America
 
 
 
 
 
 
(c)
Citizenship:
 
 
 
 
 
 
 
Armistice Capital, LLC – Delaware
Steven Boyd – United States of America
 
 
 
 
 
 
(d).  
Title of Class of Securities:
 
 
 
 
 
 
 
Common Stock, par value $0.01 per share (“Shares”)
 
 
 

 
 
(e).
CUSIP Number:
 
 
 
 
 
 
 
30233M503
 
 


       
Item 3.
If This Statement is filed pursuant to ss.240.13d-1(b) or 240.13d-2(b), or (c), check whether the person filing is a  
       
  (a)
 [_] 
Broker or dealer registered under Section 15 of the Exchange Act (15 U.S.C. 78c).
       
 
(b)
[_]
Bank as defined in Section 3(a)(6) of the Exchange Act (15 U.S.C. 78c).
 
 
 
 
 
(c)
[_]
Insurance company as defined in Section 3(a)(19) of the Exchange Act (15 U.S.C. 78c).
 
 
 
 
 
(d)
[_]
Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
 
 
 
 
 
(e)
[X]
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
 
 
 
 
 
(f)
[_]
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
 
 
 
 
 
(g)
[X]
A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
 
 
 
 
 
(h)
[_]
A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C.1813);
 
 
 
 
 
(i)
[_]
A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
 
 
 
 
 
(j)  
[_]
Group, in accordance with s.240.13d-1(b)(1)(ii)(J).
       
       
Item 4.
Ownership.    
       
  Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.  
       
  (a) Amount beneficially owned: 
     
   
Armistice Capital, LLC – 2,916,101
Steven Boyd – 2,916,101
 
  (b) Percent of class:
     
   
Armistice Capital, LLC – 19.8%
Steven Boyd – 19.8%

 

 
(c)  
Number of shares as to which the person has:
 
 
 
 
 
(i)
Sole power to vote or to direct the vote
 
 
 
 
 
 
Armistice Capital, LLC – 0
Steven Boyd – 0
 
 
 
 
(ii)  
Shared power to vote or to direct the vote
 
 
 
 
 
 
Armistice Capital, LLC – 2,916,101
Steven Boyd – 2,916,101
 
 
 
 
(iii)
Sole power to dispose or to direct the disposition of
 
 
 
 
 
 
Armistice Capital, LLC – 0
Steven Boyd – 0
 
 
 
 
(iv)  
Shared power to dispose or to direct the disposition of
 
 
 
 
 
 
Armistice Capital, LLC –2,916,101
Steven Boyd – 2,916,101
 

The percentage of Shares reported to be beneficially owned by the Reporting Persons are based on 12,619,256 Shares outstanding as of August 11, 2021, as reported in the Issuer’s Form 10-Q filed with the SEC on August 12, 2021.  Of the 2,916,101 Shares beneficially owned by the Reporting Persons, 2,131,101 of such Shares are issuable upon exercise of warrants beneficially owned by the Reporting Persons.  The amount of Shares issuable upon exercise of warrants beneficially owned by the Reporting Persons are limited due to the beneficial ownership limitations applicable to certain of the warrants.

Armistice Capital, LLC (“Armistice Capital”) is the investment manager of Armistice Capital Master Fund Ltd. (the "Master Fund"), the direct holder of the Shares, and pursuant to an Investment Management Agreement, Armistice Capital exercises voting and investment power over the securities of the Issuer held by the Master Fund and thus may be deemed to beneficially own the securities of the Issuer held by the Master Fund.  Mr. Boyd, as the managing member of Armistice Capital, may be deemed to beneficially own the securities of the Issuer held by the Master Fund.  The Master Fund specifically disclaims beneficial ownership of the securities of the Issuer directly held by it by virtue of its inability to vote or dispose of such securities as a result of its Investment Management Agreement with Armistice Capital.

 
Item 5.
Ownership of Five Percent or Less of a Class.
 
 
 
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [   ].
 
 
 
 
 
 
 
 
  
 
  

 

Item 6.
Ownership of More Than Five Percent on Behalf of Another Person.
 
 
 
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than five percent of the class, such person should be identified.  A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
 
 
 
The Master Fund, a Cayman Islands exempted company that is an investment advisory client of Armistice Capital, has the right to receive dividends from, or the proceeds from the sale of, the reported securities.
 
 
 
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.
 
 
 
If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary.  If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
 
 
 
N/A
 
 
 
Item 8.
Identification and Classification of Members of the Group.
 
 
 
If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group.  If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.
 
 
 
N/A
 
 
 
Item 9.
Notice of Dissolution of Group.
 
 
 
Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity.  See Item 5.
 
 
 
N/A
 
 
 
Item 10.
Certification.
 
 
 
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
 
  
SIGNATURE
 
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
 
 
August 13, 2021
 
(Date)
 
 
 
Armistice Capital, LLC
 
 
 
By:  /s/ Steven Boyd
 
Steven Boyd
 
Managing Member
 
 
 
 
/s/ Steven Boyd
 
Steven Boyd
  
  
 
Exhibit 99.1
JOINT FILING AGREEMENT
 
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including additional amendments thereto) with respect to the shares of Common Stock, par value $0.01 per share, of EyeGate Pharmaceuticals, Inc. This Joint Filing Agreement shall be filed as an Exhibit to such Statement. 
Dated: August 13, 2021
 
Armistice Capital, LLC
 
 
 
By:  /s/ Steven Boyd
 
Steven Boyd
 
Managing Member
 
 
 
 
/s/ Steven Boyd
 
Steven Boyd